US-REGISTERED COMPANY 
EU WAREHOUSE
PNC-27 and FOXO4-DRI are studied through different cellular pathways: membrane HDM-2 and FOXO4–p53 signalling. The evidence is predominantly preclinical.
PNC-27: the membrane HDM-2 model
PNC-27 contains a p53-derived domain and a membrane-penetrating segment. Its binding to membrane HDM-2 and pore formation are studied in cellular models. This is predominantly an in vitro and preclinical research area, rather than an established clinical therapy.
PubMed: PNC-27, membrane HDM-2 and mitochondrial membranes
FOXO4-DRI: senescence and the FOXO4–p53 interaction
FOXO4-DRI was developed to disrupt the interaction between FOXO4 and p53 in senescent cells. Foundational studies describe selective induction of apoptosis in particular senescence models and improvements in some measures of homeostasis in mice.
PubMed: targeted elimination of senescent cells
| Feature | PNC-27 | FOXO4-DRI |
|---|---|---|
| Main target | Membrane HDM-2 in studied tumour cells | FOXO4–p53 interaction in senescent cells |
| Proposed outcome | Membrane pore formation and necrosis in the model | Apoptosis of senescent cells in the model |
| Level of evidence | Predominantly cellular and preclinical data | Cellular and animal models |
Related profiles
See PNC-27, FOXO4-DRI, cellular signalling and cellular ageing and redox biology.
This content is intended solely for research and educational purposes. It is not medical advice or instructions for use in humans or animals.
Related catalogue and documentation
FOXO4-DRI, FOXO 4 DRI and FOXO4
FOXO4 is a protein name, whereas FOXO4-DRI denotes a research peptide. FOXO 4 DRI is a spaced spelling of the same search term; DRI is not a separate compound. Research on the FOXO4 protein does not establish the effects of FOXO4-DRI material.